Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel

Pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) historically have poor survival outcomes due to inherent and/or acquired chemotherapy resistance1. With the advent of CD19-specific chimeric antigen receptor (CD19-CAR) T-cell therapies, these patients are now experiencing remission at high rates2-6. For pediatric patients without access to experimental T-cell products, the availability of the FDA-approved product tisagenlecleucel (Kymriah, Novartis) has changed the treatment paradigm7, 8.

Source: Biology of Blood and Marrow Transplantation - December 4, 2021 Category: Hematology Authors: Jonas W. Ravich, Sujuan Huang, Yinmei Zhou, Patrick Brown, Ching-Hon Pui, Hiroto Inaba, Cheng Cheng, Stephen Gottschalk, Brandon M. Triplett, Challice L. Bonifant, Aimee C. Talleur Source Type: research